Excellent EU programs push health R&I but are not sufficient. Synergy with strategic initiatives in MS and a new model for impactful collaborations are needed to address the challenges for health. ERA4Health brings the opportunity to increase EU transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing EU Public Health Needs, with total duration of 7 years.
ERA4Health focuses on tackling diseases and reducing disease burden and the following challenges: 1) the increasing demand for a better quality of life and a better care of patients, 2) the need to transform public health care systems in more effective, efficient, equitable, accessible, and resilient ones and 3) the need to strengthen disease prevention and health promotion. In this view, ERA4Health objectives are:

• SO1- Support relevant medical research including clinical fields and intervention areas (prevention, diagnosis, treatment)
• SO2- Improve the utilisation of existing health technologies in clinical practice
• SO3- Build capacity, in particular in conducting Investigator Initiated Clinical Studies at EU scale
• SO4- Implement and advance the practice of RRI across the breadth of the programme

ERA4Heatlth will be implemented in 2 phases:

• Phase 1 (2 years) will implement joint calls focused on nutrition and lifestyle-related diseases, cardiovascular diseases and nanomedicine (4 in two years). In parallel, it will establish a supporting framework to overcome the challenges in launching international IICSs joint calls.
• Phase 2, if the EC approves it: additional multinational calls for IICSs and joint calls for other priority areas will be launched in accordance with the decision of the Health Programme Committee taken at the end of previous Phase 34 partners (20 from EU, 3 Third Countries associated to HE and 2 non-associated, non EU), will commit 90,510,000€, during the 3 first years, as financial support to third parties.

Výsledky

1) aktualizace strategického plánu výzkumu a inovací nadnárodními klinickými studiem iniciovanými výzkumnými pracovníky; 2) publikace výsledků a výstupů projektu, tvorba doporučených postupů; 3) vzdělávací aktivity zaměřené na zvýšení konkurenceschopnosti získat finanční podporu pro mezinárodní akademické klinické studie; 4) definování způsobilosti a výběrového řízení, jakož i podrobných pravidel financování akademických klinických studií.

Cíle udržitelného rozvoje

Masarykova univerzita se hlásí k cílům udržitelného rozvoje OSN, jejichž záměrem je do roku 2030 zlepšit podmínky a kvalitu života na naší planetě.